Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ritobegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 7/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ritobegron SCHEMBL5916906 | 1.00 | ADRB3 (0.64) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL1404071 | 1.00 | ADRB3 (0.64) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL1404072 | 1.00 | ADRB3 (0.64) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL2949688 | 0.99 | ADRB3 (0.63) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL2947591 | 0.99 | ADRB3 (0.63) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL2950593 | 0.99 | ADRB3 (0.63) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL2950589 | 0.99 | ADRB3 (0.63) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL4108225 | 0.92 | ADRB3 (0.58) | ADRB3LMNASLC6A2SLC6A4OPRM1 | |
| SCHEMBL13653975 | 0.92 | ADRB3 (0.54) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| SCHEMBL13653968 | 0.92 | ADRB3 (0.54) | ADRB3ADRB2LMNASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101657211-A | Use of lhrh antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity | AETERNA ZENTARIS GMBH DE | 2010-02-24 | — | — | CN | disclosed |
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | AETERNA ZENTARIS GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-1967202-A1 | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity | AEterna Zentaris GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | LHCGR, GNRHR, FSHR | ADRB3 562/4885ADRB2 660/4885LMNA 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.